Compare Davita Inc (DVA) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nerdwallet Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Nerdwallet Inc trades at $9.81 (market cap $580.74M). The key difference: Davita Inc is far larger — about 19.4× Nerdwallet Inc's market cap, and Davita Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Nerdwallet Inc for 45 Days on average.
| DVA | NRDS | |
|---|---|---|
Market Cap | $11.28B | $580.74M |
Volume | 650,294 | 547,586 |
Sector | Health | Media |
52-Week High | $240.96 | $15.93 |
52-Week Low | $103.87 | $7.58 |
Typical Hold Time | 113 Days | 45 Days |
Enterprise Value | $24.00B | $495.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical signals from moving averages and oscillators. The company shows strong fundamentals with revenue growth from $539M in 2022 to $837M in 2025, improving net income from losses to $49M, and attractive valuation ratios including P/E of 10.09 and P/S of 0.76. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934, but Q1 and Q4 2025 beat estimates.
Outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and a projected 27.9% upside potential. Key risks include competitive pressures in credit cards and small-business products, reliance on organic search traffic, and macroeconomic sensitivity. The stock presents value with strong profitability margins and cash flow generation despite recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
